GlassScriptPhysician profile
David Ivan Shockey
NPI 1144883174
$3,427.32
in general payments reported to CMS, 2019-2025
36 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.35 · 2023: $581 · 2024: $1,364 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,356 · Education: $27.14 · Entertainment: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,356.20 |
| Education | $27.14 |
| Entertainment | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $662.13 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $508.09 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $217.33 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $207.11 | 2022-2025 | Jardiance, Mounjaro, Kisunla |
| Corcept Therapeutics | $185.25 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $148.42 | 2023-2025 | Trelegy Ellipta |
| Inari Medical, INC. | $144.33 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $136.41 | 2023-2025 | Viberzi, Linzess |
| Novartis Pharmaceuticals Corporation | $131.78 | 2024 | |
| Csl Behring | $115.26 | 2025 | Kcentra |
| Bayer Healthcare Pharmaceuticals INC. | $91.96 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.07 | 2024-2025 | Jardiance |
| Amgen INC. | $76.05 | 2024-2025 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $74.89 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $71.54 | 2023-2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $63.43 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.83 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $53.53 | 2023 | Belsomra, Pneumovax 23, Vaxneuvance |
| Pfizer INC. | $53.05 | 2024-2025 | |
| Lundbeck LLC | $47.61 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $47.21 | 2023 | Auvelity |
| Saluda Medical Americas, INC. | $42.10 | 2024 | Evoke |
| Inspire Medical Systems, INC. | $31.27 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $26.89 | 2023 | Xarelto |
| Renalytix Ai, INC. | $26.60 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Idorsia Pharmaceuticals US INC | $22.51 | 2023 | Quviviq |
| Impulse Dynamics (USA) INC. | $20.24 | 2023 | Optimizer |
| Recordati_rare_diseases_inc. | $18.62 | 2024 | Isturisa, Signifor Lar |
| Optos, INC. | $14.63 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Ascensia Diabetes Care US INC. | $14.43 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.70 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $13.05 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shockey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.